Sub-Lobar Resection ‘New Standard of Care’ for Small-Sized NSCLC

Investigators in the CALGB 140503 recently presented the results of phase 3 of the trial at the IACSLC World Conference on Lung Cancer 2022 in Vienna. The results show that sub-lobar resection is noninferior to lobectomy with respect to disease-free survival and overall survival in patients with clinical stage T1a N0 non-small-cell lung cancer and tumors no larger than 2 cm, among other findings.